JP2001525826A - 持続放出性遅延型ゲル - Google Patents

持続放出性遅延型ゲル

Info

Publication number
JP2001525826A
JP2001525826A JP54960298A JP54960298A JP2001525826A JP 2001525826 A JP2001525826 A JP 2001525826A JP 54960298 A JP54960298 A JP 54960298A JP 54960298 A JP54960298 A JP 54960298A JP 2001525826 A JP2001525826 A JP 2001525826A
Authority
JP
Japan
Prior art keywords
composition
biologically active
protein
sustained release
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP54960298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001525826A5 (enExample
Inventor
ゴールデンバーグ，メリル・シーモア
ビークマン，アリス・シー
クー，チエン・ホワ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2001525826A publication Critical patent/JP2001525826A/ja
Publication of JP2001525826A5 publication Critical patent/JP2001525826A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP54960298A 1997-05-16 1998-05-18 持続放出性遅延型ゲル Ceased JP2001525826A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85797397A 1997-05-16 1997-05-16
US08/857,973 1997-05-16
US91290297A 1997-08-15 1997-08-15
US08/912,902 1997-08-15
PCT/US1998/010013 WO1998051348A2 (en) 1997-05-16 1998-05-18 Sustained-release delayed gels

Publications (2)

Publication Number Publication Date
JP2001525826A true JP2001525826A (ja) 2001-12-11
JP2001525826A5 JP2001525826A5 (enExample) 2005-12-08

Family

ID=27127437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54960298A Ceased JP2001525826A (ja) 1997-05-16 1998-05-18 持続放出性遅延型ゲル

Country Status (18)

Country Link
EP (1) EP0981374B1 (enExample)
JP (1) JP2001525826A (enExample)
KR (1) KR20010012374A (enExample)
AU (1) AU7491898A (enExample)
BG (1) BG64860B1 (enExample)
BR (1) BR9809117A (enExample)
CA (1) CA2289196C (enExample)
CZ (1) CZ299180B6 (enExample)
DE (1) DE69838750T2 (enExample)
EA (1) EA199901013A1 (enExample)
ES (1) ES2294814T3 (enExample)
HU (1) HUP0003393A3 (enExample)
IL (1) IL132814A0 (enExample)
NO (1) NO995591D0 (enExample)
PL (1) PL199565B1 (enExample)
SK (1) SK286437B6 (enExample)
WO (1) WO1998051348A2 (enExample)
YU (1) YU58599A (enExample)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006219501A (ja) * 2002-10-25 2006-08-24 Pfizer Prod Inc 懸濁形態でのアリール複素環活性薬物の蓄積製剤
JP2008184401A (ja) * 2007-01-29 2008-08-14 Medorekkusu:Kk 低温充填ゼリー組成物とその製造方法
JP2008542282A (ja) * 2005-05-23 2008-11-27 ナチュラル オータナティブス インターナショナル β−アラニンの徐放のための組成物及び方法
JP2009531298A (ja) * 2006-02-22 2009-09-03 アイサイエンス・インターベンショナル・コーポレーション 脈絡膜上薬物送達のための装置および製剤
JP2010524981A (ja) * 2007-04-24 2010-07-22 バイオコンパティブルズ ユーケー リミテッド 脳腫瘍の治療のための微小球
US9636332B2 (en) 2012-11-08 2017-05-02 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US9636253B1 (en) 2013-05-03 2017-05-02 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US9956114B2 (en) 2014-06-20 2018-05-01 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
US10952894B2 (en) 2010-10-15 2021-03-23 Clearside Biomedical, Inc. Device for ocular access
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
JP2021525607A (ja) * 2018-06-04 2021-09-27 スパームヴァイタル アクティーゼルスカブ ハイドロゲルを調製するための機能化キット
JPWO2021193981A1 (enExample) * 2020-03-26 2021-09-30
JP2022506417A (ja) * 2018-11-06 2022-01-17 ナショナル キャンサー センター アルギン酸ベースの注入型ヒドロゲルシステム
US11596545B2 (en) 2016-05-02 2023-03-07 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003200609B2 (en) * 1998-05-18 2006-02-23 Amgen Inc. Biodegradable sustained-release alginate gels
US6432449B1 (en) * 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
JP2000256216A (ja) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd ゲル組成物
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
CA2396431A1 (en) * 1999-11-29 2001-05-31 Advanced Research And Technology Institute, Inc. Sustained percutaneous delivery of a biologically active substance
FR2823119B1 (fr) * 2001-04-05 2004-02-20 Seppic Sa Adjuvant d'immunite contenant un cation metallique complexe et vaccin le contenant
CN113423386A (zh) * 2019-10-01 2021-09-21 美国倍利年制药有限公司 治疗或预防肥胖和体重管理的方法
CN114533653B (zh) * 2020-11-26 2023-12-22 上海凯茂生物医药有限公司 一种人促红素杂合Fc融合蛋白相变型制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5416979B2 (enExample) * 1972-01-08 1979-06-26
US4241099A (en) * 1979-02-26 1980-12-23 Tiemstra Peter J Pectin formulations, products and methods having delayed-action acidulants
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4744933A (en) * 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
JPS645460A (en) * 1987-06-29 1989-01-10 Sanei Kagaku Kogyo Kk Production of delaying gelatinous material
JPH0794583B2 (ja) * 1989-12-15 1995-10-11 株式会社大塚製薬工場 高含水高分子ゲル
IT1245383B (it) * 1991-03-28 1994-09-20 Eniricerche Spa Composizione acquosa gelificabile avente tempo di gelificazione ritardato
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
KR960006730B1 (ko) * 1993-02-11 1996-05-23 재단법인한국화학연구소 에멀젼 네트웍(emulsion network)을 이용한 약물의 피부 전달체계
GB9708773D0 (en) * 1997-04-30 1997-06-25 Reckitt & Colmann Prod Ltd Organic compositions

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006219501A (ja) * 2002-10-25 2006-08-24 Pfizer Prod Inc 懸濁形態でのアリール複素環活性薬物の蓄積製剤
JP2008542282A (ja) * 2005-05-23 2008-11-27 ナチュラル オータナティブス インターナショナル β−アラニンの徐放のための組成物及び方法
JP2013224310A (ja) * 2005-05-23 2013-10-31 Natural Alternatives Internatl β−アラニンの徐放のための組成物及び方法
US11944703B2 (en) 2006-02-22 2024-04-02 Clearside Biomedical, Inc. Ocular injector and methods for accessing suprachoroidal space of the eye
JP2009531298A (ja) * 2006-02-22 2009-09-03 アイサイエンス・インターベンショナル・コーポレーション 脈絡膜上薬物送達のための装置および製剤
US11752101B2 (en) 2006-02-22 2023-09-12 Clearside Biomedical, Inc. Ocular injector and methods for accessing suprachoroidal space of the eye
JP2008184401A (ja) * 2007-01-29 2008-08-14 Medorekkusu:Kk 低温充填ゼリー組成物とその製造方法
JP2010524981A (ja) * 2007-04-24 2010-07-22 バイオコンパティブルズ ユーケー リミテッド 脳腫瘍の治療のための微小球
US10952894B2 (en) 2010-10-15 2021-03-23 Clearside Biomedical, Inc. Device for ocular access
US12090088B2 (en) 2010-10-15 2024-09-17 Clearside Biomedical, Inc. Device for ocular access
US9636332B2 (en) 2012-11-08 2017-05-02 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US9931330B2 (en) 2012-11-08 2018-04-03 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US12350261B2 (en) 2012-11-08 2025-07-08 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US10722396B2 (en) 2013-05-03 2020-07-28 Clearside Biomedical., Inc. Apparatus and methods for ocular injection
US9937075B2 (en) 2013-05-03 2018-04-10 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10555833B2 (en) 2013-05-03 2020-02-11 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US9636253B1 (en) 2013-05-03 2017-05-02 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US12201558B2 (en) 2013-05-03 2025-01-21 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US9770361B2 (en) 2013-05-03 2017-09-26 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10517756B2 (en) 2013-05-03 2019-12-31 Clearside Biomedical, Inc Apparatus and methods for ocular injection
US11559428B2 (en) 2013-05-03 2023-01-24 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
US9956114B2 (en) 2014-06-20 2018-05-01 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
US11596545B2 (en) 2016-05-02 2023-03-07 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US12127975B2 (en) 2016-08-12 2024-10-29 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
JP2021525607A (ja) * 2018-06-04 2021-09-27 スパームヴァイタル アクティーゼルスカブ ハイドロゲルを調製するための機能化キット
JP7510355B2 (ja) 2018-06-04 2024-07-03 スパームヴァイタル アクティーゼルスカブ ハイドロゲルを調製するための機能化キット
JP2022506417A (ja) * 2018-11-06 2022-01-17 ナショナル キャンサー センター アルギン酸ベースの注入型ヒドロゲルシステム
JP7312822B2 (ja) 2018-11-06 2023-07-21 ナショナル キャンサー センター 注入型ヒドロゲルシステムおよび病変の標識方法
JPWO2021193981A1 (enExample) * 2020-03-26 2021-09-30

Also Published As

Publication number Publication date
CZ396399A3 (cs) 2000-04-12
ES2294814T3 (es) 2008-04-01
CA2289196A1 (en) 1998-11-19
NO995591L (no) 1999-11-15
HUP0003393A2 (hu) 2001-02-28
IL132814A0 (en) 2001-03-19
DE69838750D1 (de) 2008-01-03
PL199565B1 (pl) 2008-10-31
CZ299180B6 (cs) 2008-05-14
BG103914A (en) 2000-07-31
EA199901013A1 (ru) 2000-06-26
NO995591D0 (no) 1999-11-15
SK154399A3 (en) 2000-07-11
EP0981374A2 (en) 2000-03-01
EP0981374B1 (en) 2007-11-21
KR20010012374A (ko) 2001-02-15
CA2289196C (en) 2007-08-07
AU7491898A (en) 1998-12-08
HUP0003393A3 (en) 2001-03-28
YU58599A (sh) 2000-12-28
SK286437B6 (sk) 2008-10-07
DE69838750T2 (de) 2008-10-30
WO1998051348A2 (en) 1998-11-19
BG64860B1 (bg) 2006-07-31
WO1998051348A3 (en) 1999-02-18
PL336887A1 (en) 2000-07-17
BR9809117A (pt) 2000-08-01

Similar Documents

Publication Publication Date Title
JP2001525826A (ja) 持続放出性遅延型ゲル
ES2283052T3 (es) Geles de alginato de liberacion sostenida.
RS58599B1 (sr) Postupak za neinvazivno određivanje genetičkih varijacija
JP2002515419A (ja) 生分解性徐放性アルギン酸塩ゲル
US20010007673A1 (en) Sustained-release delayed gels
BG64642B1 (bg) Фармацевтичен състав с продължително освобождаване на лекарствени средства, капсулирани в микрочастици на хиалуронова киселина
JP2004513914A (ja) 非経口的投与可能な微粒子
CN1263472A (zh) 缓释延迟凝胶剂
AU2005200949B2 (en) Sustained-Release Delayed Gels
MXPA99010284A (en) Sustained-release delayed gels
MXPA99009388A (en) Sustained-release alginate gels
MXPA00011231A (en) Biodegradable sustained-release alginate gels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090210

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090707